Home › Urothelial (Transitional Cell) Carcinoma › New York › New York City
Urothelial (Transitional Cell) Carcinoma clinical trials in New York City, NY
22 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RecruitingPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RecruitingObservational study
- NYU Grossman School of Medicine, New York
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
RecruitingPhase 1/2
- Memorial Sloan Kettering Cancer Center ( Site 1031), New York
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
RecruitingPhase 1/2
- Icahn School of Medicine at Mount Sinai, New York
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
- Columbia University Irving Medical Center, New York
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
RecruitingPhase 1
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
RecruitingPhase 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RecruitingPhase 1
- New York Cancer & Blood Specialists, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
RecruitingPhase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Centre (BAIC), New York
- and 2 more
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
RecruitingPhase 3
- Research Site, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RecruitingPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Recruiting
- Integrated Medical Professionals, New York
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
RecruitingPhase 1
- MSK, New York
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
RecruitingObservational study
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
RecruitingPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, New York
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- Houston, TX19 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- Boston, MA11 studies
- San Antonio, TX11 studies
- Austin, TX10 studies
- Orange, CA10 studies
Other studies in New York City
- Breast Cancer136 studies
- Non-Small Cell Lung Cancer121 studies
- Cancer (all types)109 studies
- Prostate Cancer103 studies
- Metastatic Cancer93 studies
- Colorectal Cancer78 studies
- Ovarian Cancer69 studies
- Lung Cancer60 studies
- Multiple Myeloma60 studies
- Pancreatic Cancer60 studies
- Endometrial Cancer52 studies
- Acute Myeloid Leukemia51 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.